A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene.
暂无分享,去创建一个
John K Field | A. Pettitt | T. Liloglou | P. Sherrington | J. Field | Ke Lin | Triantafillos Liloglou | Gillian G Johnson | Paul D Sherrington | Anthony Carter | Ke Lin | Andrew R Pettitt | A. Carter | G. Johnson
[1] W. R. Bishop,et al. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[2] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[3] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[4] S. Kuersten,et al. The power of the 3′ UTR: translational control and development , 2003, Nature Reviews Genetics.
[5] C. Salvarani,et al. The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. , 2007, Clinical and experimental rheumatology.
[6] D. Lane,et al. Cancer. p53, guardian of the genome. , 1992, Nature.
[7] John C Reed,et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Peller. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. , 1998, Seminars in cancer biology.
[9] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[10] A. Brookes. The essence of SNPs. , 1999, Gene.
[11] A. Pettitt,et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.
[12] M. Gordon. Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication , 2009 .
[13] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[14] M. Murphy,et al. Polymorphisms in the p53 pathway , 2006, Oncogene.
[15] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[16] I. Bleiweiss,et al. p53 haplotype determination in breast cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[17] D. Christiani,et al. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. , 2003, Lung cancer.
[18] A. Pettitt,et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia , 2006, Leukemia.
[19] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[20] A. Pettitt,et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia , 2004, British journal of haematology.
[21] Miranda Thomas,et al. Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.
[22] G. Dotto,et al. p21(WAF1/Cip1): more than a break to the cell cycle? , 2000, Biochimica et biophysica acta.
[23] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[24] J. Vijg,et al. SNP discovery in associating genetic variation with human disease phenotypes. , 2005, Mutation research.
[25] O. Pereira-smith,et al. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate , 2004, The EMBO journal.
[26] Z. Livneh,et al. p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. , 2006, Molecular cell.
[27] J. Lotem,et al. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. , 1993, Blood.
[28] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[29] H. Lincet,et al. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. , 2000, Cancer letters.
[30] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[31] Jong-Yeon Shin,et al. p21WAF/CIP1/SDI1 is upregulated due to increased mRNA stability during hydroxyurea-induced senescence of human fibroblasts , 2005, Mechanisms of Ageing and Development.
[32] Adrian Wiestner,et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia , 2004, The Lancet.
[33] V. Rotter,et al. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.
[34] J. Siedlecki,et al. Regulatory functions of 3'UTRs. , 2001, Biochemical and biophysical research communications.
[35] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[36] R. Ralhan,et al. Novel polymorphism in p21waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer , 2000, Oncogene.
[37] A. Gartel. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. , 2005, Leukemia research.
[38] D. Oscier,et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.
[39] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[40] N. Saitou,et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.
[41] E. Newcomb,et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .
[42] P. V. D. van den Berk,et al. A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification , 2007, The Journal of experimental medicine.
[43] A. Pettitt,et al. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. , 2003, Blood.
[44] A. Fritscher-Ravens. Endoscopic ultrasound evaluation in the diagnosis and staging of lung cancer. , 2003, Lung cancer.
[45] C. Lawrence,et al. An update on the role of translesion synthesis DNA polymerases in Ig hypermutation. , 2005, Trends in immunology.
[46] P. Loehrer. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .
[47] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[48] R. Birgander,et al. Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.
[49] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[50] E. Tajara,et al. Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? , 2003, Cancer genetics and cytogenetics.
[51] M. Miura,et al. Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP , 1998, Oncogene.
[52] A. Pettitt,et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. , 2002, Blood.
[53] Patrick Dumont,et al. The Codon 47 Polymorphism in p53 Is Functionally Significant*[boxs] , 2005, Journal of Biological Chemistry.
[54] N. Park,et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. , 2004, Gynecologic oncology.
[55] T. Möröy,et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.
[56] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[57] P. D. Lee,et al. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. , 1995, Human molecular genetics.
[58] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[59] Michael A. Crawford,et al. Acknowledgement to the 2000 Reviewers , 2000, Annals of Nutrition and Metabolism.
[60] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.